By admin 
The Interagency Autism Coordinating Committee (IACC) convened on Thursday for a meeting that signaled a fundamental and polarizing shift in the federal government’s approach to autism research and policy. In a move that has sent shockwaves through the scientific and advocacy communities, committee members explicitly discussed vaccines as a potential trigger for autism, directly challenging decades of settled science and global public health consensus. This development marks a significant departure from previous iterations of the committee, where the debunked link between immunizations and autism was largely excluded from serious policy discussions. The meeting’s primary objective was the review and approval of a new, 336-page strategic plan, a document that reshapes the federal research agenda by pivoting away from a "genetics-first" model toward controversial environmental and biological theories.
The shift in tone was palpable from the outset. Laura Cellini, the founder and CEO of the nonprofit Elucidate ASD and a prominent member of the committee, articulated a philosophy of radical openness toward all potential causes of autism. Cellini argued that the federal government should not "close the door" on any potential trigger, specifically naming glutamate, aspirin, and vaccinations as areas requiring further investigation. This "open door" policy represents a victory for a subset of parents and advocates who have long felt that federal agencies ignored environmental factors in favor of genetic studies. However, for the broader scientific community, this openness is viewed as a dangerous regression into misinformation. The theory that vaccines cause autism has been exhaustively investigated by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the Institute of Medicine, all of which have found no evidence of a causal link. The original 1998 study that sparked the controversy was retracted by The Lancet after it was discovered to be fraudulent, yet its echoes remain a central feature of the current committee’s discourse.
While the word "vaccine" does not explicitly appear in the working draft of the new strategic plan, the meeting’s public commentary was dominated by the topic. Several public members shared emotional testimonies, attributing their children’s "regression"—a loss of previously acquired social or language skills—directly to vaccination schedules. In a notable departure from past committee behavior, none of the federal or public members challenged these assertions or provided scientific counterpoints. Greg Robinson, the director of public policy at the Autistic Self Advocacy Network (ASAN), noted that this silence indicates a "new normal" for the IACC. Robinson, who is autistic himself, expressed grave concern over the implications of this shift, pointing to the real-world consequences of vaccine hesitancy. He cited the recent measles-related deaths in Pennsylvania as a stark reminder of the dangers posed by the erosion of public trust in immunizations. For advocates like Robinson, the committee’s willingness to entertain debunked theories is not merely a matter of academic debate but a public health crisis in the making.
The transformation of the IACC can be traced back to January, when Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. reshaped the panel’s membership. Kennedy, a longtime critic of federal vaccine policy, appointed individuals whose views closely align with his own, effectively steering the committee toward a "medicalized" view of autism that focuses on "cures" and "triggers." This ideological overhaul has met with fierce resistance from the established autism research community. In response to the committee’s new direction, a group of independent researchers and advocates formed a separate advisory body to provide a scientific counter-narrative and to combat what they describe as a rising tide of federal misinformation. Critics have also slammed the new IACC for a lack of transparency, citing the rapid-fire approval process and the exclusion of dissenting voices during initial planning sessions.
The strategic plan approved on Thursday is a radical document that seeks to nearly double federal autism funding from $390 million to $747 million. While the plan is technically a set of nonbinding recommendations for Congress, it serves as a powerful blueprint for how federal tax dollars will be allocated in the coming years. Most significantly, the plan de-emphasizes the role of genetics, which has been the cornerstone of autism research for decades. Instead, it calls for a massive influx of funding into under-researched and scientifically contested areas such as metabolic stress, inflammation, diet, and the role of folate. Specifically, the plan highlights leucovorin—a form of folinic acid—and other folate-based therapies as potential treatments. This is despite a 2025 review of scientific literature indicating a profound lack of evidence for the efficacy of these treatments in a broad autism population.
IACC Chair Sylvia Fogel opened the meeting with a defense of the committee’s "urgency," contrasting it with what she described as twenty years of federal inaction. Fogel argued that the community has been asking for a change in direction for decades and that the committee is finally "acting" rather than merely talking. Fogel’s leadership has been a lightning rod for controversy. When she released the 336-page plan on July 17, she initially gave the public only three days to review the massive document and submit comments. Following a significant public outcry and pressure from major research organizations, she eventually extended the deadline, though she reportedly did so with significant reluctance. The procedural friction has led some members, including former IACC participants, to question whether the committee is adhering to the Federal Advisory Committee Act (FACA), which mandates transparency and public engagement for such bodies.
Despite the overarching controversy, the plan does contain elements that have garnered broad support. Researchers and self-advocates alike praised the plan’s focus on co-occurring conditions that frequently affect autistic individuals, such as epilepsy, gastrointestinal issues, and sleep disorders. There is also a shared sentiment that genetic research, while vital, may have been disproportionately funded relative to practical supports that improve the daily lives of autistic people. Sam Crane, a former public member of the IACC and a prominent autistic advocate, noted that the recognition of motor and communication issues within the plan is a positive step forward. Crane acknowledged that while genetics is important, the field was perhaps "overfunded" at the expense of clinical services and communication access.
However, the "good" in the plan is, for many, overshadowed by its perceived flaws. Robinson and other advocates pointed out that the strategic plan is noticeably silent on issues critical to the adult autistic population, such as employment, housing, and independent living. Instead of focusing on the "social model" of disability—which seeks to adapt society to accommodate neurodivergent individuals—the plan leans heavily toward a "medical model" that views autism as a biological pathology to be treated or prevented. Robinson warned that this shift pushes away from models that have historically maximized the ability of autistic people to be integrated into their communities. Furthermore, the plan’s focus on "regression" suggests an search for an external biological "insult"—such as an infection or an environmental toxin—that triggers autism, a theory that remains largely speculative.
A particularly contentious point during the meeting was Chair Fogel’s use of artificial intelligence to analyze the thousands of public comments received. Fogel reported that the AI analysis showed 50% of commenters were "aligned" with the plan and 40% were "mixed." However, she provided little data on the methodology used by the software or how it categorized complex, nuanced feedback. This reliance on AI was criticized by Scott Robertson, a senior policy adviser at the Department of Labor and an autistic committee member. Robertson expressed concern that the AI might oversimplify or misinterpret the community’s concerns. He also voiced frustration over the committee’s internal process, noting that members were provided with over 1,000 pages of additional comments and revisions just hours before the final vote. Robertson argued that such a timeline made it "infeasible" for members to adequately process the information and requested a delay in the vote, citing a statement from 13 major disability organizations that urged the committee not to rush the process.
Fogel remained undeterred by these objections. She dismissed the calls for delay, suggesting that the plan was a response to "two decades of public comments" that had been ignored by previous administrations. In a pointed rebuttal to the advocacy groups requesting more time, Fogel noted that some of those very organizations had been represented on the committee for twenty years and had failed to achieve the results she is now pursuing. "I, as chair, am moving to act," she declared, signaling a clear intent to bypass traditional consensus-building in favor of rapid policy implementation.
The committee’s new direction is already finding favor in the highest levels of the executive branch. Last week, Secretary Kennedy announced the National Autism Missing and Endangered Person Alert initiative, a program designed to address "elopement" or wandering, which is a leading cause of injury and death for autistic children. This initiative was a direct recommendation from the committee. Furthermore, reports suggest that Kennedy and National Institutes of Health (NIH) Director Jay Bhattacharya are preparing to adopt new federal initiatives focused on "profound autism," a term used to describe individuals who require 24-hour care and have significant cognitive or communication challenges. While the term is controversial within the neurodiversity movement, it has become a central focus for the current IACC.
The meeting concluded with the formal adoption of the strategic plan, passing with 26 "yes" votes, one "no" vote from Scott Robertson, and 13 abstentions. The high number of abstentions reflects the deep unease felt by many federal representatives and public members who are caught between the committee’s new leadership and the established scientific community. As the plan moves to Congress and federal agencies, it sets the stage for a period of intense debate over the future of autism research in America. While Sylvia Fogel views the plan as "opening a door" to new possibilities, many in the scientific and advocacy worlds fear that it is a door that leads back to a period of scientific uncertainty and public health risk. The IACC’s shift represents more than just a change in research priorities; it is a fundamental realignment of how the United States understands and supports its autistic population.
